Wai Chun Bio-Technology (HKG:0660) reported a loss attributable to the shareholders of HK$13.7 million for the six months ended Dec. 31, compared with HK$6.7 million in the previous year, according to a Friday filing with the Hong Kong Stock Exchange.

Loss per share was HK$0.0797, compared with HK$0.0393 in the prior-year period.

The company's revenue was HK$161.1 million, compared with HK$190.3 million the previous year.